Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Cytokine-induced killer cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cytokine-induced killer cells or CIK cells are a group of immune effector cells featuring a mixed T- and natural killer (NK) cell-like phenotype. They are generated by ex vivo incubation of human peripheral blood mononuclear cells (PBMC) or cord blood mononuclear cells with interferon-gamma (IFN-γ), anti-CD3 antibody, recombinant human interleukin (IL-) 1 and recombinant human interleukin (IL)-2.
Preparation method of human cytokine-induced killer cells
InactiveCN102732481APromote proliferationRaise the ratioBlood/immune system cellsHybrid peptidesPeripheral blood mononuclear cellCytotoxicity
The invention discloses a preparation method of human cytokine-induced killer cells, comprising the following steps: coating a cell culture flask with a coating buffer containing effective amount of fusion protein and human CD3 monoclonal antibody before culturing precursor cells of human CIK cells, and adding the human CD3 monoclonal antibody in the whole process of inducing and culturing the human CIK cells, wherein the fusion protein is human intercellular adhesion molecule-1 functional domain and human fibronectin functional domain fusion protein, and the concentration of the human CD3 monoclonal antibody in the cell culture solution is lower than the concentration of the human CD3 monoclonal antibody in the coating buffer. According to the invention, ex-vivo expansion efficiency of peripheral blood mononuclear cells and the proportion of CD3 / CD56 double positive cells in the CIK cells are significantly raised, the cytotoxicity activity of the CIK cells is enhanced, thus the effect of cellular immunity treatment is raised.
Owner:SHENZHEN YOUNGCELL BIO TECH
Efficient CIK amplifying method
The invention discloses an efficient CIK amplifying method, in particular to a method for cell populations, namely cytokine-induced killer cells utilizing in-vitro cell factors for efficiently inducing mononuclear cell expressions CD3 and CD56 of peripheral blood, wherein the cell populations have killing functions. The cultivation method for the CIK efficiently expressing CD3+CD56 comprises the following steps that the peripheral blood of a healthy person or a patient is collected in a sterile mode, after the peripheral blood is diluted through a saline solution with the same volume, a Ficoll lymphocyte separating medium is used for separating mononuclear cells, in the CIK cell inducing process, CD3 monoclonal antibodies (CD3mAb), CD28 monoclonal antibodies (CD28mAb), interferon-gamma (IFN-gamma), interleukin-2(IL-2) and interleukin 1alpha (IL-1alpha) are added, cultivation is carried out for 13-16 days to obtain cells, a CIK cell preparation is prepared, and flow cytometry detection and microorganism detection are carried out. According to the CIK cultivation method, the CIK number can be increased to be 6*10<9> or over 6*10<9> in two weeks, the cell survival rate can be increased to be 99% or over 99%, and the double-positive proportion of the CD3+CD56+cells reaches 30% or over 30%.
Owner:UNION STEMCELL & GENE ENG
Method for stimulating rapid proliferation of CIK (Cytokine-induced Killer) cells by using DC (Dendritic Cells)
InactiveCN103255105AIncrease the number ofShort amplification timeBlood/immune system cellsDendritic cellCytokine
The invention discloses a method for stimulating the rapid proliferation of CIK (Cytokine-induced Killer) cells by using DC (Dendritic Cells). The method comprises the following steps: separating peripheral blood monouclear cells (PBMC); performing induction culture on cytokine-induced killer cells, i.e., performing induction culture on the CIK cells; performing induction culture on the DC; and detecting the phenotype CD3<+>CD56<+> of the CIK cells. According to the method, the numbers of the CIK cells are amplified substantially within a short period while the CD3<+>CD56<+> ratio of the surfaces of the CIK cells is not changed sharply, so that the amplification time of the CIK is shortened obviously; and the proliferation rate is improved at the same time. Therefore, the important scientific research value is obtained.
Owner:爱瑞康医疗投资管理(北京)有限公司
Preparation of high efficiency immune active cell and method of using for anti tumour
InactiveCN1869206AMammal material medical ingredientsBlood/immune system cellsChemical treatmentAbnormal tissue growth
This invention relates to producing of high efficiency immune cell group and method of its using to tumor preventing, it belongs to biotechnology field. Dendritic cell is induced by oligonucleotide and cytokine, cell is induced and wounded by the cytokine, then dendritic cell and wounded cell are mixed with certain ratio to get new kind cell group that cultured by immune effect cell group dendritic that induced by oligonucleotide and the wounded cell. Compared to cell group cultured by wounded cell and dendritic cell, the proliferation activity is stronger. The cell poisonous activity is higher than the wounded cell. The oligonucleotide can be artificially synthesized. Immune cell group that anti cancer activity is higher than the wounded cell can also be induced to patient that operation opportunity is gone and tumor antigen is hard to get. It can be used to self-body tumor curing, chemical treatment and assistant curing to radiotherapy.
Owner:DALIAN UNIV OF TECH
Anti-angiogenic cellular agent for cancer therapy
InactiveUS20080260701A1Effective treatmentTherapeutically effectiveBiocideGenetic material ingredientsAbnormal tissue growthHematopoietic cell
The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.
Owner:HOPE ERNEST G
Immunity enhancing reagent
ActiveCN104887717APromote activationIncreased proliferationViral/bacteriophage medical ingredientsAntibody ingredientsReceptorT lymphocyte
The invention discloses an immunity enhancing reagent comprising AAVs carrying molecule encoding genes of antibodies at immunodetection points, wherein the immunodetection points are one or several from PD-1, PD-L1 and CTLA-4. The AAVs carrying the molecule encoding genes of the antibodies at different immunodetection points are combined with each other, T cells, natural killer cells, cytotoxic T lymphocytes or cell factor induced killer cells and other immune cells are infected in vitro, and the antibodies at the immunodetection points are expressed and secreted after the infected immune cells are fed back to bodies of patients suffering from tumors, so that the combination of receptors at the immunodetection points and ligands of the receptors is blocked, the transfer of an immunosuppression signal is effectively blocked, the immune tumor suppression microenviroment is destroyed, the immune cell killing capacity is improved, and furthermore the curative effect of adoptive immune therapy is improved.
Owner:ICARTAB BIOMEDICAL
Method for culturing dendritic cells (DC) and cytokine-induced killer cells (D-CIK) and applications thereof
InactiveUS20080213895A1Effective trainingThe process is convenient and fastUnknown materialsCancer antigen ingredientsDendritic cellCytokine
A mass production of dendritic cells (DC) and cytokine-induced killer cells (D-CIK) cells from the umbilical cord blood or peripheral blood via the activation with a cellular activator “Koyo” derived from the purified tumor cells during the aggregation and proliferation of the purified tumor cells is provided. A preparation of a vaccine with the dendritic cells (DC) and D-CIK cells is used to improve the symptoms of infectious diseases, cancers, metastasised cancers and auto-immune disorders.
Owner:KOYO INT HLDG CORP
CIK (Cytokine-Induced Killer Cell) capable of knocking down expression of endogenous PD-1 (programmed death 1) and preparation method and application thereof
ActiveCN107312800AEnhance tumor killing activityReduced expression levelGenetically modified cellsMammal material medical ingredientsGene targetsAbnormal tissue growth
The invention discloses a CIK (Cytokine-Induced Killer Cell) capable of knocking down endogenous PD-1 (programmed death 1) expression and a preparation method and application thereof. The invention provides a method for preparing a CIK preparation capable of knocking down endogenous PD-1 expression, comprising the following steps: A) inducing the differentiation of PBMC to CIK in vitro by using cytokines; B) transferring a vector capable of knocking down endogenous PD-1 expression into the CIK obtained in step A), culturing for 13 to 16 days and harvesting a cell, thereby obtaining the CIK preparation capable of knocking down the endogenous PD-1 expression, wherein the vector capable of knocking down endogenous PD-1 expression contains a plurality of tandem encoded genes targeting miRNAs of PD-1, and the number of the encoded genes is 2 to 30. Experimental results show that the vector can significantly reduce the expression level of endogenous PD 1 in the CIK, thereby significantly enhancing the tumor-killing activity of a CIK cell.
Owner:BEIJING SHUNLEI BIOTECHNOLOGY CO LTD
Application of dendritic cell combined with cytokine-induced killer cell in lung cancer treatment
InactiveCN102357101AMammal material medical ingredientsBlood/immune system cellsDendritic cellSide effect
The invention relates to an application of dendritic cells combined with cytokine-induced killer cells in lung cancer treatment. The invention prepares sensitized DC cells and CIK cells; the two cells are transfused back to patients with lung cancer, which can effectively prolong the survival time of the patients; and the toxic and side effect is low.
Owner:SHANGHAI CHEST HOSPITAL
Application of DC-CIK (Dendritic Cell-Cytokine-Induced Killer) cells in preparation of medicine used for resisting HIV (Human Immunodeficiency Virus) infection
InactiveCN102512448AHas a lethal effectPromote maturityAntiviralsMammal material medical ingredientsDendritic cellHuman immunodeficiency
The invention belongs to the field of biomedicine and discloses application of DC-CIK cells in preparation of a medicine used for resisting HIV infection. Through a lot of experiments, the inventor discovers that when CIK cells impacted by HIV and DC cells are co-cultured, the CIK cells can obviously promote maturation of the DC cells. When the DC and CIK cells are combined for use, the DC and CIK cells have mutual promotion presentation and a function for killing cells infected by HIV. After 30 days of the DC-CIK cell infusion, the number of CD4T cells of a HIV infector is obviously increased, the killing function of NK (Natural Killer) and CIK cells is enhanced, and HIV viral load is obviously restrained. Thus, kill cells induced by co-cultured dendritic cells and cytokines can be applied to the preparation of the medicine used for resisting HIV infection.
Owner:JIANGSU PROVINCIAL CENT FOR DISEASE PREVENTION & CONTROL
Dendritic cell, preparation method thereof and application
The invention provides a dendritic cell, a preparation method thereof and application. Concretely, the invention provides application of combination of the dendritic cell and cytokine-induced killer cell to prepare a medicine for treating or inhibiting liver cancer, wherein the dendritic cell is capable of specifically recognizing liver cancer nidus. According to the embodiment in the invention, the combination of the dendritic cell and the cytokine-induced killer cell is capable of effectively treating or inhibiting liver cancer.
Owner:WUHAN HAMILTON BIOTECH
Method for intensifying functions of cytokine-induced killer cells
InactiveCN104434973AIncrease the number ofFunction increaseMammal material medical ingredientsCancer antigen ingredientsDendritic cellViral disease
The invention provides a method for intensifying functions of cytokine-induced killer cells. The method comprises the following steps: analyzing and obtaining an epitope through a bioinformatics analysis method, fusing the epitope and Ii-Kye into an epitope peptide, anchoring the epitope peptide on MHC-II molecules on the surfaces of dendritic cells, and infecting the dendritic cells with recombinant adenovirus rAd-RNAi-SOCS1; and further carrying out co-cultivation on the dendritic cells and cytokine-induced killer cells, and treating tumor-bearing mice with co-cultivated cells, so that the processed dendritic cells are capable of activating the cytokine-induced killer cells, and intensifying the significant killing functions of the cytokine-induced killer cells on related tumors. The invention provides a method for treating tumors employing activated cells; and the core technology of the method has reference significance on treatment of other viroses.
Owner:深圳市金佳禾生物医药湖北有限公司
Applications of BCG-PSN (BCG-polysaccharide nuceic acid) in promoting proliferation of CIK cells (cytokine-induced killer cells) and in improving anti-tumor activity of CIK cells
PendingCN107446886APromote proliferationImprove tumor killing abilityCulture processBlood/immune system cellsDiseaseActivity factor
The invention relates to applications of BCG-PSN (BCG-polysaccharide nuceic acid). The BCG-PSN is capable of promoting proliferation of CIK cells (cytokine-induced killer cells) and capable of improving an anti-tumor effect of the CIK cells; the expression of related cytotoxic activity factors is also enhanced when the anti-tumor efficiency is improved; and the CIK cells, which accept induction culture of the BCG-PSN, are applicable to cell therapy of tumor diseases.
Owner:HUNAN SIQI BIOPHARM
Frozen resuscitation solution for multiple cytokine induced killer cells, and application thereof
InactiveCN108018260AHigh activityProliferation rate is fastCulture processBlood/immune system cellsCytokineDextran
The invention discloses a frozen resuscitation solution for multiple cytokine induced killer cells, and an application thereof. The frozen resuscitation solution for multiple cytokine induced killer cells comprises albumin and dextran. The multiple cytokine induced killer cells obtained through the subsequent induction and amplification process of single karyocytes obtained through resuscitation using the frozen resuscitation solution have the advantages of fast proliferation rate, high induced differentiation efficiency and good cell viability.
Owner:SOUTH CHINA INSTITUDE OF BIOMEDICINE
Fusion protein used for preparing human cytokine induced killer cells
InactiveCN103483454AEnhance tumor killing activityPromote proliferationBlood/immune system cellsHybrid peptidesPeripheral blood mononuclear cellCytotoxicity
Owner:SHENZHEN YOUNGCELL BIO TECH
Immune preparation for treating tumor and preparation method thereof
InactiveCN105832769APrevent recurrenceInhibit transferTumor rejection antigen precursorsMammal material medical ingredientsDiseaseDendritic cell
The invention discloses an immune preparation for treating tumor; the immune preparation contains dendritic cells (DC) loaded with a tumor antigen and cytokine-induced killer cells (CIK), the concentration of the DC loaded with the tumor antigen in a culture liquid is 1*10<7> to 1*10<8>, and the concentration of the CIK in the culture liquid is 1*10<9> to 1*10<10>. The invention further provides a preparing method of the immune preparation for treating tumor; the preparing method comprises the steps: collection of mononuclear cells of peripheral blood; isolation and culture of the DC and the CIK; extraction of a tumor antigen gene and viral vector packaging; transfection of the DC with a virus mediated tumor antigen gene; and co-culture of the DC loaded with the tumor antigen and the CIK. The accuracy of positioning of re-transported immune cells in a human body can be improved. The objective defect of a conventional cell immunotherapy technology in the same field is not good in solid tumor treatment effect can be effectively improved; adaptation diseases are wide, and the use is safe and effective.
Owner:SHANGHAI PRECISION DIAGNOSTICS CO LTD
Pharmaceutical composition and kit for treating cancers
InactiveCN106955352AImprove survival rateExtend your lifePharmaceutical delivery mechanismMammal material medical ingredientsDendritic cellInducer
The invention provides a pharmaceutical composition and a kit for treating cancers. The pharmaceutical composition comprises an antibody resisting a programmed cell death receptor 1 and co-cultured dendritic cells and cytokine-induced killer cells; the kit comprises the antibody resisting a programmed cell death receptor 1 and an inducer of the co-cultured dendritic cells and cytokine-induced killer cells, which are separately arranged. The pharmaceutical composition or the kit can be effectively used for treating cancers, and particularly are applicable to treatment of advanced refractory solid tumors or hematological malignancy.
Owner:SHUNHAO CELL BIOTECHNOLOGY (TIANJIN) CO LTD
Cytokine-induced killer cell activity-associated protein and application thereof
InactiveCN104328166APeptide/protein ingredientsMicrobiological testing/measurementCell activityActive component
The invention provides a cytokine-induced killer cell activity-associated protein and an application thereof, relates to an immune cell activity-associated protein and especially relates to influences of haptoglobin on variation of cell activity of cytokine-induced killer (CIK) cells. The expression of the haptoglobin at a protein level and a nucleic acid level is significantly increased with enhancement of the activity of the CIK cells, which means that a positive correlativity exists between the haptoglobin and the activity of the cytokine-induced killer cells. The invention provides an index of detection of an activity intensity of the CIK cells, or provides basis for researching a recombinant protein and a relative medicine which are used for improving an immune system with the haptoglobin as an active component.
Owner:曹劲松
DC (Dendritic cell)-CIK (Cytokine-induced killer cell) immune cell modified by both AFP (Alpha-fetoprotein) and HBsAg (Hepatitis B surface antigen) antigen genes as well as preparation method and application of the cell
InactiveCN109055317AInfluence cultivationAffect differentiationGenetically modified cellsVirus peptidesCalcium biphosphateDendritic cell
The invention belongs to the technical field of biotechnology, and particularly relates to a DC (Dendritic cell)-CIK (Cytokine-induced killer cell) immune cell modified by both AFP (Alpha-fetoprotein)and HBsAg (Hepatitis B surface antigen) antigen genes as well as a preparation method and application of the cell. The preparation method provided by the invention comprises the following steps: firstly constructing a recombinant plasmid pHAGE-AFP-HBsAg; then the recombinant plasmid pHAGE-AFP-HBsAg, a helper plasmid psPAX2 and pMD2G being co-transfected to 293T cells with calcium phosphate transfection reagent, to obtain recombinant lentivirus AFP-HBsAg; subsequently, infecting DC cells with the recombinant lentivirus AFP-HBsAg, to obtain the DC cells modified by the AFP-HBsAg; and finally, co-culturing the DC cells modified by the AFP-HBsAg with the CIK cells, to obtain the DC-CIK immune cells.
Owner:武汉大学人民医院
Freezing resuscitation solution for multi-cytokine-induced killer cells, and applications thereof
The invention discloses a freezing resuscitation solution for multi-cytokine-induced killer cells, and applications thereof, wherein the freezing resuscitation solution comprises albumin and dextran.According to the present invention, the multi-cytokine-induced killer cells obtained through the induction and amplification of the mononuclear cells resuscitated with the freezing resuscitation solution have advantages of rapid proliferation, high induction differentiation efficiency and good cell viability.
Owner:SOUTH CHINA INSTITUDE OF BIOMEDICINE
Immune cell with tumor treatment function and application thereof
InactiveCN108753715AIncrease the amount of infiltrationImprove anti-tumor effectMammal material medical ingredientsBlood/immune system cellsDendritic cellOncolytic adenovirus
The invention relates to an immune cell with a tumor treatment function and application thereof. The immune cell provided by the invention is an exogenously infused immune cell; the immune cell has acapability of inhibiting tumor together with oncolytic adenovirus, an immune microenviroment of tumor is firstly broken, an inflammation environment is caused, then the immune cell can take functionsinto play well in the inflammation environment, and a tumor treatment effect can be thus improved; the immune cell is a cytotoxic T cell (CTL), a dendritic cell, a cell factor induced killer cell (CIK) or a tumor infiltration lymphocyte (TIL). The immune cell is combined with the oncolytic virus in oncolytic virus mediated gene therapy, then tumor inhibition can be further relieved, anti-tumor immunoreactions can be enhanced, and the purposes of improving immunity of a patient self and treating tumor can be achieved.
Owner:广州沙艾生物科技有限公司
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
ActiveUS20180312606A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCytotoxicityBispecific antibody
Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.
Owner:WUHAN YZY BIOPHARMA CO LTD
A method for efficiently amplifying cik
The invention discloses an efficient CIK amplifying method, in particular to a method for cell populations, namely cytokine-induced killer cells utilizing in-vitro cell factors for efficiently inducing mononuclear cell expressions CD3 and CD56 of peripheral blood, wherein the cell populations have killing functions. The cultivation method for the CIK efficiently expressing CD3+CD56 comprises the following steps that the peripheral blood of a healthy person or a patient is collected in a sterile mode, after the peripheral blood is diluted through a saline solution with the same volume, a Ficoll lymphocyte separating medium is used for separating mononuclear cells, in the CIK cell inducing process, CD3 monoclonal antibodies (CD3mAb), CD28 monoclonal antibodies (CD28mAb), interferon-gamma (IFN-gamma), interleukin-2(IL-2) and interleukin 1alpha (IL-1alpha) are added, cultivation is carried out for 13-16 days to obtain cells, a CIK cell preparation is prepared, and flow cytometry detection and microorganism detection are carried out. According to the CIK cultivation method, the CIK number can be increased to be 6*10<9> or over 6*10<9> in two weeks, the cell survival rate can be increased to be 99% or over 99%, and the double-positive proportion of the CD3+CD56+cells reaches 30% or over 30%.
Owner:UNION STEMCELL & GENE ENG
Serum-free cell cryopreservation liquid for cell cryopreservation and cryopreservation method thereof
The invention relates to a cell cryopreservation solution for cryopreservation of immune cells and a cryopreservation method thereof, wherein killer cells induced by cytokines are particularly good. The cell cryopreservation liquid does not contain serum and is prepared from the following components: (1) a mixed basic culture medium, (2) dimethyl sulfoxide (DMSO), (3) a serum substitute and (4) dextran. The serum-free cryopreservation liquid is characterized in that the serum-free cryopreservation liquid is a mixed culture medium and a serum substitute so as to achieve a serum-free cryopreservation function. After immune cells, especially natural killer cells, are unfrozen, 80% or more of the cell poisoning function and functional cell markers can be maintained, and high-concentration cell loading capacity is achieved.
Owner:PRECISION BIOTECH TAIWAN CORP
an immune-enhancing reagent
ActiveCN104887717BPromote activationIncreased proliferationViral/bacteriophage medical ingredientsAntibody ingredientsReceptorT lymphocyte
The invention discloses an immunity enhancing reagent comprising AAVs carrying molecule encoding genes of antibodies at immunodetection points, wherein the immunodetection points are one or several from PD-1, PD-L1 and CTLA-4. The AAVs carrying the molecule encoding genes of the antibodies at different immunodetection points are combined with each other, T cells, natural killer cells, cytotoxic T lymphocytes or cell factor induced killer cells and other immune cells are infected in vitro, and the antibodies at the immunodetection points are expressed and secreted after the infected immune cells are fed back to bodies of patients suffering from tumors, so that the combination of receptors at the immunodetection points and ligands of the receptors is blocked, the transfer of an immunosuppression signal is effectively blocked, the immune tumor suppression microenviroment is destroyed, the immune cell killing capacity is improved, and furthermore the curative effect of adoptive immune therapy is improved.
Owner:ICARTAB BIOMEDICAL
Activated lymphocytes comprising cytokine-induced killer cells and preparation method therefor
PendingUS20220160763A1High anticancer activityMaximized anticancer activityMammal material medical ingredientsBlood/immune system cellsSide effectWhite blood cell
The present invention relates to activated lymphocytes comprising cytokine-induced killer cells in which CD8+CD56+NKG2D+ cells are present at a proportion of 20% or more, and a preparation method therefor, and more particularly, to activated lymphocytes comprising cytokine-induced killing cells which have high tumor cell killing abilities and growth rates and are almost free of side effects because they do not require the combined administration of interleukin-2, and a preparation method therefor.
Owner:GREENCROSSCELL
Process for production of cytokine-induced killer cells
InactiveCN102575231BImprove qualityGood treatment effectAntibacterial agentsAntimycoticsCell massBiochemistry
Owner:TAKARA HOLDINGS
Preparation method of cytokine-induced killer cells
PendingCN112175904AHigh yieldIncreased lethal potentialBlood/immune system cellsCell culture active agentsAntiendomysial antibodiesCD3-Epsilon
The invention discloses a preparation method of cytokine-induced killer cells. The method comprises the following steps of: separating a collected human peripheral blood sample to obtain PBMNC; inoculating the PBMNC into a culture flask coated with a recombinant humanized anti-CD25mAb monoclonal antibody for culture; and transferring non-adherent cells obtained in the step S2 and culture supernatant into a culture flask coated with a recombinant humanized anti-CD3 epsilon monoclonal antibody, and supplementing INF-gamma for continuous culture. According to the preparation method of the cytokine-induced killer cells, CIK cells are induced and amplified by adopting a traditional culture process of CD25 monoclonal antibody improved CIK cells, so that the yield of CD3+ CD56+ cells is increased, the proportion of CD3+ CD4+ cells is reduced, the killing potential of the CIK cells on K562 and SK-MEL-5 cells is effectively improved, and the preparation method has important significance for formulating a preparation method and quality standard of a clinical-grade CIK cell preparation.
Owner:北广再生医学科技(广东)有限公司
Method for production of cell mass containing cytokine-induced killer cell
InactiveCN102027104AEfficient treatment effectDisease treatment is usefulCell culture supports/coatingBlood/immune system cellsCell massCytokine
Owner:TAKARA HOLDINGS +1
A kind of cik cell culture medium
InactiveCN106987558BIncrease multipleHigh cell surface antigen contentCulture processBlood/immune system cellsMicrosphereCell culture media
The invention relates to the biotechnology field of biotechnolog, in particular to a CIK (cytokine induced killer cell) medium, which comprises a basic medium and an additive added into the basic medium. In terms of a final concentration, the additive comprises the following components: 20-30microg / mL polylysine, 5-15mg / mL BCG-polysaccharide, 0.03-0.04micromol / mL sodium selenite, 5-8microg / mL 4-hydroxyethylpiperazine ethane sulfonic acid, 2-4microg / L reduced glutathione, 8-12microg / mL adenosine deaminase, 2-3mg / mL IFN-gamma sustained release microsphere, 1.5-2mg / mL IL-2 sustained release microspheres, and 4-6mL / L autologous plasma. Through intercoordination and combined action of all the components, the CIK medium provided by the invention can provide sufficient nutrition and good environment needed by cell growth and proliferation, and can improve the activity and multiplication capacity of immune cells.
Owner:DONGGUAN BOALAI BIOLOGICAL TECH CO LTD
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com